Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies

OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. This post hoc analysis evaluated patients receiving tofacitinib monotherapy or combination therapy, as well as those who switched from monotherapy to combination therapy (mono→combo) or vice versa (co...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy, Wollenhaupt, Jürgen, Takiya, Liza, Maniccia, Anna, Kwok, Kenneth, Wang, Lisy, van Vollenhoven, Ronald F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761286/
https://www.ncbi.nlm.nih.gov/pubmed/29435359
http://dx.doi.org/10.1136/rmdopen-2017-000491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761286/
https://www.ncbi.nlm.nih.gov/pubmed/29435359
http://dx.doi.org/10.1136/rmdopen-2017-000491

Ejemplares similares